The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.

Tag:

Pfizer

Latest Headlines

Latest Headlines

Merck KGaA teams up with Pfizer to spotlight new lupus therapies

Rival drugmakers Merck KGaA and Pfizer are putting their cash and expertise into a new effort to better understand lupus, tapping the Broad Institute for a Big Data approach to help map out the disease and light the way for future drug candidates.

Pfizer gets FDA green light for Nexium OTC launch as AZ braces for competition

AstraZeneca has been pulling out all the stops in trying to preserve blockbuster Nexium's revenues for as long as it can. Now, the FDA has approved an over-the-counter version of the drug--but thanks to a 2012 agreement, those sales are on their way to Pfizer.

Tomorrow's cardio blockbusters: Inside 'the next big leap' in controlling cholesterol

Thanks to genomic sequencing, some heart-healthy mutants and billions of dollars spent on R&D, rival drug developers are bearing down on a promising new way of treating the scourge of high cholesterol. And with the first FDA applications likely coming in the next year, the nascent field's trailblazers are vying for the top spot with blockbuster aspirations.

GSK teams up to apply Big Data to target validation

The combination of genomics and bioinformatics expertise now needed for target validation has led drugmakers to look outside their walls for skills, with Pfizer teaming with the Broad Institute on such a project. Now GlaxoSmithKline has set up its own initiative and called for its Big Pharma peers to get involved.

Pfizer says PCSK9 study was a winner, boosting its chances in hectic R&D race

Pfizer says the Phase IIb study for its closely-watched PCSK9 cholesterol drug bococizumab (RN316) scored the primary endpoint on all doses, which should help steer a massive Phase III program that started out last fall with 22,000 patients.

AstraZeneca, Pfizer say direct-delivery programs can win with patients

Time is running out before generics descend on Nexium, the stomach drug that rakes in nearly $4 billion a year for AstraZeneca. And in an effort to conserve sales, the British drugmaker is going where it's gone once before: a direct-to-patient delivery program it hopes will keep customers in its grasp.

Pfizer's targeted Xalkori outshines chemo in trial of untreated lung cancer patients

Pfizer said its targeted cancer drug Xalkori trounced chemotherapy in a trial of previously untreated patients with a particular type of lung cancer. The study showed for the first time that up-front treatment with Xalkori staves off cancer growth better than other treatments in patients whose tumors test positive for ALK-gene abnormalities.

'Breakthrough' nod for Pfizer MenB candidate sets up showdown with Bexsero

Pfizer's approval pathway for its meningococcal B vaccine just got shorter. On Thursday, the FDA designated the candidate, dubbed rLP2086, as a breakthrough therapy, which will speed its trip through the regulatory process--and put it in a head-to-head battle with Novartis' Bexsero.

Pfizer snags a 'breakthrough' tag for its meningitis vaccine in a race with Novartis

Pfizer picked up the FDA's breakthrough therapy designation for an in-development vaccine against meningococcal disease, a common cause of meningitis, lighting the path for an accelerated approval as the drugmaker looks to expand its vaccine portfolio beyond the blockbuster Prevnar 13.

They're no Coca-Cola, but top biopharma brands Pfizer, Biogen and Merck still worth billions

How much is a pharma company's brand worth? More than $4 billion, if that pharma company is Pfizer. It's the most valuable pharma brand in the U.S., according to Brandirectory's latest iteration of the Billion Dollar Brands Club. For a company that's among the biggest prescription drug marketers in the world, that might not be so surprising.